PHASE 1 CLINICAL TRIAL OF A NOVEL HER2 VACCINE FOR PATIENTS WITH DCIS

Medicine & Life Sciences

1. Breast Cancer 3 22%
2. Breast Diseases 6%
3. Breast Neoplasms 19%
4. Carcinoma, Intraductal, Noninfiltrating 100%
5. Cervical Intraepithelial Neoplasia 6%
6. Clinical Trials 6%
7. Clinical Trials, Phase I 54%
8. Disease-Free Survival 9%
9. Epitopes 8%
10. Extranodal Extension 7%
11. Gynecology 5%
12. Hormones 7%
13. Immunity 8%
14. Immunization 17%
15. Immunologic Monitoring 6%
16. Investigational Drugs 7%
17. Long Term Adverse Effects 7%
18. Oncogene Proteins 5%
19. Preliminary Data 5%
20. Recurrence 11%
21. Research Ethics Committees 5%
22. Research Personnel 10%
23. Safety 14%
24. Subunit Vaccines 6%
25. T-Lymphocytes 9%
26. Therapeutics 6%
27. United States Food and Drug Administration 10%
28. Vaccination 12%
29. Vaccines 55%